Sedatives

Ehave KetaDASH Subsidiary Commences Data Collection for Potential Patients and Partnering Clinics

Retrieved on: 
Thursday, May 20, 2021
Psychoactive drugs, Drugs, Health sciences, Antidepressants, Arylcyclohexylamines, Ketones, Nicotinic antagonists, Sedatives, Ketamine, Therapy, Healthcare industry

b'MIAMI, May 20, 2021 (GLOBE NEWSWIRE) -- Ehave, Inc. (OTC Pink: EHVVF) (the \xe2\x80\x9cCompany\xe2\x80\x9d), a provider of digital therapeutics for the psychedelic and mental health sectors, announced today its KetaDASH subsidiary has commenced data collection for potential patients and partnering clinics.

Key Points: 
  • b'MIAMI, May 20, 2021 (GLOBE NEWSWIRE) -- Ehave, Inc. (OTC Pink: EHVVF) (the \xe2\x80\x9cCompany\xe2\x80\x9d), a provider of digital therapeutics for the psychedelic and mental health sectors, announced today its KetaDASH subsidiary has commenced data collection for potential patients and partnering clinics.
  • KetaDASH is available to ketamine clinics and qualified patients whose healthcare provider has prescribed it as a treatment.
  • The KetaDASH platform utilizes proprietary software developed by Ehave which allows patients and medical professionals to view detailed reports on the ketamine therapy\xe2\x80\x99s progress.
  • More information on KetaDASH is available at www.ketadash.com .\nKetamine therapy has turned out to be a life-changing alternative to antidepressants for many patients.

PharmaTher Announces FDA Approval of Ketamine IND In The Treatment of Parkinson’s Disease

Retrieved on: 
Monday, May 17, 2021
Psychoactive drugs, Drugs, Neurochemistry, Antidepressants, Hallucinations, Ketamine, Sedatives, Psychedelic drug

The FDA IND is our first of many we will aim to obtain, and we are one of the few psychedelics-focused biotech companies that have an IND approved by the FDA for a recognized psychedelic drug.

Key Points: 
  • The FDA IND is our first of many we will aim to obtain, and we are one of the few psychedelics-focused biotech companies that have an IND approved by the FDA for a recognized psychedelic drug.
  • The IND paves the way for us to expeditiously evaluate ketamine and other psychedelics via the FDA regulatory pathway in various mental illness, neurological and pain disorders.
  • There is currently no cure for Parkinson\xe2\x80\x99s disease, although some drug combinations are used to treat the disease symptoms.
  • The possible therapeutic effect of low-dose ketamine on LID was noted in a retrospective analysis of PD patients who received ketamine for pain relief.

Lamar Odom Reborn: New Documentary Follows NBA Athlete's Journey to Beat Addiction and Anxiety Through the Use of Psychedelic Medicines

Retrieved on: 
Monday, May 17, 2021
Branches of biology, Psychoactive drugs, Drugs, NMDA receptor antagonists, Nicotinic antagonists, General anesthetics, Chloroarenes, Sedatives, Ketamine, Ibogaine, Odom, Post-traumatic stress disorder

Lamar admits he self-medicated and avoided professional interventions given the stigma attached with mental health treatment.\n"Admitting you are depressed or asking for help is a challenge for anyone," says Odom.

Key Points: 
  • Lamar admits he self-medicated and avoided professional interventions given the stigma attached with mental health treatment.\n"Admitting you are depressed or asking for help is a challenge for anyone," says Odom.
  • "My hope is that sharing my journey in Reborn will open a dialogue for millions of people.
  • Just months after my first ketamine and ibogaine treatments, I felt physically well enough to play professional basketball again.
  • "Ketamine, however, is an FDA-approved anesthetic that has been hailed as a miracle for treating depression, anxiety, PTSD, addiction, and more.

Marinus Pharmaceuticals Reschedules First Quarter 2021 Financial Results Conference Call

Retrieved on: 
Thursday, May 13, 2021
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical trials, Psychoactive drugs, Drugs, GABAA receptor positive allosteric modulators, Neurochemistry, Ketones, Sedatives, Anticonvulsants, Chloroarenes, Ganaxolone, Antidepressant, Allosteric modulator, Ketamine

b'Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders.

Key Points: 
  • b'Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders.
  • Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, antidepressant and anti-anxiety effects.
  • Ganaxolone is being developed in IV and oral dose formulations intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings.
  • The company has initiated a Phase 3 trial in refractory status epilepticus.

Braxia Scientific Opens First Ketamine Therapy Clinic in Quebec; Enters Joint Venture with Neurotherapy Montreal, A Leading Brain Injury Solutions Clinic for Adults and Children

Retrieved on: 
Thursday, May 13, 2021
Branches of biology, Neuroscience, Clinical medicine, Neurotechnology, Neuropsychology, Antidepressants, Nicotinic antagonists, Sedatives, Ketamine, Nasal administration, Neurofeedback, Neuromodulation

"\nThe new clinic is located within Neurotherapy Montreal\'s state of the art 14,000 square foot facility providing leading mental health and rehabilitation services, more specifically, brain-based solutions for children and adults using the latest neuromodulation and neuroscience technologies.

Key Points: 
  • "\nThe new clinic is located within Neurotherapy Montreal\'s state of the art 14,000 square foot facility providing leading mental health and rehabilitation services, more specifically, brain-based solutions for children and adults using the latest neuromodulation and neuroscience technologies.
  • "Since opening our clinics less than 3 years ago, we have administered over 3,000 Intravenous Ketamine Infusionsand over 60 Intranasal Ketamine treatments.
  • Through Braxia Health clinics, these treatments have shown highly significant rapid-acting efficacy to patients with depression.
  • "\nThe clinic is to be operated as a joint venture, owned equally by the Company and NMC.

Delic's Acquisition Target, Ketamine Infusion Centers, Announces Proposal to Acquire 2 Additional Clinic Locations

Retrieved on: 
Tuesday, May 11, 2021
Psychoactive drugs, Drugs, Medical specialties, General anesthetics, Arylcyclohexylamines, Chloroarenes, Nicotinic antagonists, Sedatives, Ketamine, Post-traumatic stress disorder, KIC

("DELIC" or "the "Company") (CSE: DELC) (OTCQB: DELFC) a psychedelic wellness platform, is pleased to announce that its acquisition target (under binding letter agreement see news release dated February 4, 2021), Ketamine Infusion Centers ("KIC"), proposes to acquire two (2) additional licensed ketamine clinics in Arizona.

Key Points: 
  • ("DELIC" or "the "Company") (CSE: DELC) (OTCQB: DELFC) a psychedelic wellness platform, is pleased to announce that its acquisition target (under binding letter agreement see news release dated February 4, 2021), Ketamine Infusion Centers ("KIC"), proposes to acquire two (2) additional licensed ketamine clinics in Arizona.
  • "KIC is the leading name in high quality care and incredible outcomes for its patients and this move helps grow that reputation significantly.
  • As a vital part of the Delic platform, KIC will continue to offer wellness and benefits for many people suffering from anxiety, depression and PTSD.
  • Ketamine Infusion Centers unique model and passion to obtain the highest patient outcomes and purely evidence-based practices is a perfect fit in the Delic ecosystem.

Marinus Pharmaceuticals to Provide Business Update and Announce First Quarter 2021 Financial Results on May 13, 2021

Retrieved on: 
Friday, May 7, 2021
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical trials, Psychoactive drugs, Drugs, GABAA receptor positive allosteric modulators, Neurochemistry, Ketones, Sedatives, Anticonvulsants, Chloroarenes, Ganaxolone, Antidepressant, Allosteric modulator, Ketamine

b'Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders.

Key Points: 
  • b'Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders.
  • Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, antidepressant and anti-anxiety effects.
  • Ganaxolone is being developed in IV and oral dose forms intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings.
  • The company has initiated a Phase 3 trial in refractory status epilepticus.

Bexson Biomedical Granted USPTO Patent On Proprietary Ketamine Formulation

Retrieved on: 
Thursday, April 29, 2021
Psychoactive drugs, Drugs, Neurochemistry, Arylcyclohexylamines, Dissociative drugs, Ketones, Nicotinic antagonists, Sedatives, Ketamine, United States patent law, Pain management, Patent

b'SANTA BARBARA, Calif., April 29, 2021 /PRNewswire/ -- Bexson Biomedical, Inc., aresearch-stage company developing therapies and delivery solutions for pain management, addiction and mental health indications, announced today that the U.S. Patent and Trademark Office (USPTO) has granted Bexson U.S. Pat.

Key Points: 
  • b'SANTA BARBARA, Calif., April 29, 2021 /PRNewswire/ -- Bexson Biomedical, Inc., aresearch-stage company developing therapies and delivery solutions for pain management, addiction and mental health indications, announced today that the U.S. Patent and Trademark Office (USPTO) has granted Bexson U.S. Pat.
  • 10,973,780, describing pharmaceutical formulations and treatment methods including the company\'s BB106 ketamine therapy.
  • This patent represents Bexson\'s first application of these innovations to enable a subcutaneous ketamine delivery platform designed for management of pain disorders and mental health conditions.
  • The patent process is a long road and we are pleased to see this first one be issued," said Gregg Peterson, Bexson co-founder and CEO.\nThe company is engaging FDA to prepare for clinical trials evaluating its patented ketamine formula delivered subcutaneously.

Alto Ingredients, Inc. to Release First Quarter 2021 Results

Retrieved on: 
Thursday, April 29, 2021
Sedatives, Chemical substances, Branches of biology, Alcohols, Disinfectants, Ethanol, Teratogens

If you are unable to participate in the live call, the webcast will be archived for replay on the Alto Ingredients website for one year.

Key Points: 
  • If you are unable to participate in the live call, the webcast will be archived for replay on the Alto Ingredients website for one year.
  • In addition, a telephonic replay will be available at 8:00 p.m. Eastern Time on Wednesday, May 12, 2021 through 8:00 p.m. Eastern Time on Wednesday, May 19, 2021.
  • The pass code will be 3595104.\nAlto Ingredients, Inc. (ALTO), formerly known as Pacific Ethanol, Inc., is a leading producer of specialty alcohols and essential ingredients.
  • The company is focused on products for four key markets: Health, Home & Beauty; Food & Beverage; Essential Ingredients; and Renewable Fuels.

Marinus Pharmaceuticals to Present at Multiple Upcoming Investor Conferences

Retrieved on: 
Wednesday, April 28, 2021
Biotechnology, Pharmaceutical, Health, Psychoactive drugs, Drugs, GABAA receptor positive allosteric modulators, Ketones, Neurochemistry, Sedatives, Chloroarenes, Anticonvulsants, Ganaxolone, Antidepressant, Ketamine, Allosteric regulation

Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, antidepressant and anti-anxiety effects.

Key Points: 
  • Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, antidepressant and anti-anxiety effects.
  • Ganaxolone is being developed in IV and oral dose formulations intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings.
  • The company has initiated a Phase 3 trial in refractory status epilepticus.
  • For more information visit www.marinuspharma.com .\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210428006117/en/\n'